Tag: Financing

BOCA RATON, FL, June 10, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced a strategic partnership with Exponent, a leading Solana-native yield strategy platform. This collaboration will see dfdvSOL, a liquid staking token (LST) adopted by DeFi Dev Corp., integrated into Exponent’s innovative fixed-yield and leverage yield farming vaults.

With this integration, Exponent users can deploy dfdvSOL across three key yield strategies, each tailored to different risk and return preferences:

Experienced Public Company Executive to Lead Financial Strategy and Support Newton’s Continued Growth

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Timbercreek Financial Corp. (TSX: TF) (the "Company") announced today that it has obtained the approval of the Toronto Stock Exchange (the "TSX") to commence a normal course issuer bid (the “NCIB”) with respect to its common shares (the “Shares”). The NCIB will commence on June 12, 2025 and will terminate on the earlier of June 11, 2026 or the date on which the Company has purchased the maximum number of Shares permitted under the NCIB.

HOUSTON, June 10, 2025 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE: WSR) (“Whitestone” or the “Company”) today announced that its Board of Trustees has declared a monthly cash dividend of $0.045 per share on the Company's common shares and operating partnership units for the third quarter of 2025.   The dividend represents a quarterly amount of $0.135 per share, and an annualized amount of $0.54 per share.

Company moves forward accelerating its business objectives

Tuebingen, Germany, June 10, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, today announced that the first patient has been dosed in their Phase Ib clinical trial of its lead candidate HRX-215. The trial is evaluating the safety and efficacy of HRX-215, an orally available small-molecule inhibitor of MKK4, in patients undergoing partial liver resection due to liver metastases deriving from colorectal cancer. HXR-215 is designed to treat advanced-stage liver disease by increasing the regenerative capacity of hepatocytes. An initial data readout is planned for the second half of 2025.

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that IPC repurchased a total of 125,600 IPC common shares (ISIN: CA46016U1084) during the period of June 2 to 6, 2025 under IPC’s normal course issuer bid / share repurchase program (NCIB).

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Compass Diversified (NYSE:CODI), Civitas Resources, Inc. (NYSE: CIVI), Open Lending Corporation (NASDAQ:LPRO), and West Pharmaceutical Services, Inc. (NYSE:WST). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.